key: cord-0715478-qxirwn9d
authors: Margulis, Michael; Erster, Oran; Roth, Shira; Mandelboim, Michal; Danielli, Amos
title: A magnetic modulation biosensing-based molecular assay for rapid and highly sensitive clinical diagnosis of COVID-19
date: 2021-09-30
journal: J Mol Diagn
DOI: 10.1016/j.jmoldx.2021.08.012
sha: e6b4cff19a8379b55361458f2f361f2639524887
doc_id: 715478
cord_uid: qxirwn9d

Rapid and sensitive detection of human pathogens, such as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is an urgent and challenging task for clinical laboratories. Currently, the gold standard test for SARS-CoV-2-specific ribonucleic acid (RNA) is based on reverse transcription quantitative polymerase chain reaction (RT-qPCR), which relies on target amplification by Taq polymerase and uses a fluorescent resonance energy transfer (FRET)-based hydrolysis probe. Although this method is accurate and specific, it is also time consuming. To rapidly detect the presence of the viral RNA in clinical samples, we describe a new molecular assay that combines a highly sensitive magnetic modulation biosensing (MMB) system, rapid thermal cycling, and a modified double-quenched hydrolysis probe. Using in vitro transcribed SARS-CoV-2 RNA targets spiked in PCR-grade water, we found that the calculated limit of detection of the MMB-based molecular assay was 1.6 copies per reaction. Testing 309 RNA extracts from 170 confirmed RT-qPCR SARS-CoV-2-negative individuals (30 of which are positive to other respiratory viruses) and 139 RT-qPCR SARS-CoV-2-positive patients ([Formula: see text]) resulted in 97.8% sensitivity, 100% specificity, and 0% cross-reactivity. The total turnaround time of the MMB-based assay is 30 minutes, which is 3–4 times faster than a standard RT-qPCR. By adjusting the primers and the probe set, the platform can be easily adapted to detect most of the pathogens that are currently being diagnosed by RT-qPCR.

The outbreak of the coronavirus disease 2019 (COVID-19) emphasized the need for fast, sensitive, and specific diagnostic tools for virus surveillance 1 . Current diagnosis of the acute phase of the COVID-19 is based on direct detection of either viral antigens or viral ribonucleic acids (RNA) in nasopharyngeal, oropharyngeal, or mid-turbinate swab samples. Antigentargeting tests are simple to use, have fast turnaround times, and allow rapid testing for pointof-care applications 2 . However, compared with viral RNA-targeting tests, their sensitivity is low, especially during the initial stages of the disease, which limits their adoption and implementation 3, 4 .

Direct detection of SARS-CoV-2 RNA is based on amplification of the specific viral RNA sequences by reverse transcription quantitative polymerase chain reaction (RT-qPCR), which theoretically allows detection of as little as a single copy of a target RNA 5, 6 . Overall, the RT phase, the real time monitoring, and the high number of amplification cycles (45) are time consuming, and therefore the turnaround time of a standard RT-qPCR system is 90-120 minutes, which hinders its use for rapid screening.

Currently, rapid screening can use several devices that are characterized by their small footprint, short sample handling time, fast turnaround time, and simple operational procedures.

These devices are based on either reverse transcription loop-mediated isothermal amplification (RT-LAMP) 7, 8 , isothermal nicking and extension amplification reaction (NEAR) 9 , or on conventional RT-PCR amplification (GeneXpert, Cepheid, Sunnyvale, CA, USA; Visby Medical, San Jose, CA, USA; Accula, Mesa Biotech, San Diego, CA, USA). NEAR-based assays are fast (e.g., 13 min) and convenient, but recently, concerns have been raised regarding the performance of these assays, suggesting a high rate of false-negative results, especially in samples with lower viral load 10, 11 . The sensitivity of RT-PCR-based assays is on par with that of the gold standard RT-qPCR assays, but the turnaround time is longer (e.g., 45 min).

(GeneXpert product information). In RT-LAMP, NEAR-and RT-PCR-based assays, the products of the reaction are visualized by either detection of increased fluorescence or by a simple color change 12, 13 . To reach a detectable fluorescent signal or a color change and retain high sensitivity, long reaction times are used. To minimize the turnaround time while maintaining high sensitivity and specificity, new optical detection methods must be explored.

Recently, to reduce the background fluorescence in RT-qPCR assays and facilitate the detection of target DNA sequences using 1-2 fewer amplification cycles, Wilson et al. employed a novel hydrolysis probe, termed a double-quenched ZEN probe 14, 15 , which uses two quenchers instead of a single quencher, thus reducing the distance between the fluorophore and the quencher to only nine bases ( Figure 1A ). In the method presented here, we combined a modified double quenched hydrolysis probe ( Figure 1B ) with a highly sensitive optical J o u r n a l P r e -p r o o f detection system, termed magnetic modulation biosensing (MMB) [16] [17] [18] , to develop a novel SARS-CoV-2 molecular assay that overcomes the limitations of existing small footprint devices while maintaining the sensitivity and specificity of RT-qPCR-based assays. Basic principles of the MMB-based SARS-CoV-2 molecular assay are presented in Figure 2 .

The modified double-quenched hydrolysis probe has a biotin on the same 5' nucleotide as the fluorescent molecule ( Figure 1B) 19 . Thus, following separation of the fluorescent molecule from the quenchers by Taq polymerase activity, the fluorescent molecule remains attached to the biotin molecule. Upon completion of a conventional RT-PCR amplification step, streptavidin-coupled magnetic beads are added to the sample and capture the biotinylated fluorescent molecules (Figure 2 ). In MMB, to increase the sensitivity of fluorescence detection, an oscillating external magnetic field gradient is applied to the sample, attracting the beads from the entire solution volume and concentrating them in a small detection area, as shown in the Supplemental Figure S1A ). The oscillating magnetic field gradient moves the bead aggregate from side to side, in and out of a laser beam, thereby separating the fluorescent signal from the background noise of unbound fluorescent molecules (Supplemental Figure S1B ). The amplitude of the oscillating signal is proportional to the concentration of the biotinylated fluorescent molecules, which in turn, depends on the initial concentration of the target and the number of amplification cycles (Supplemental Figure S1C ). Compared with direct optical detection of the fluorescent molecules, as performed by RT-qPCR, MMB-based detection is ~150 times more sensitive 20 .

To minimize the total assay time, we used shorter and fewer amplification cycles, which may have compromised the efficiency of the PCR reaction, releasing fewer fluorescent molecules to the solution. However, the weaker fluorescence signal was compensated for by the superior optical detection of the MMB system and by the reduced background noise of the modified double-quenched hydrolysis probe. Overall, the total turnaround time of the MMB-based assay is 30 minutes from RNA sample to result, which is approximately 3-4 times faster than a standard RT-qPCR protocol.

The rapid turnaround time and the use of commercially-available reagents, accompanied by the high clinical sensitivity and specificity, facilitate the adoption of the MMB-based assay for rapid SARS-CoV-2 screening. Moreover, by adjusting the primers and the probe set, the assay can be easily adapted to detect a wide variety of pathogens. While the general principles of the MMB platform have previously been described and implemented for detecting the Ibaraki virus (an agent of epizootic disease) 21 , as well as for rapidly determining chicken sex in ovo 19 , this report is the first to describe its implementation for molecular detection of human pathogens.

J o u r n a l P r e -p r o o f

All experiments involving collection and testing of biological materials (swab samples) from human subjects were performed according to guidelines and protocols approved by the institutional review board of Sheba Medical Center in Israel.

Nasopharyngeal swabs from hospitalized COVID-19-positive patients were collected by trained personnel, placed into a standard viral transport medium (VTM), and transported at 4⁰ C for RNA extraction and RT-qPCR testing at the Central Virology Laboratory (CVL) of the Israeli Ministry of Health. The RNA extraction was performed either by the PSS magLEAD instrument (Precision System Science, Chiba, Japan) or by the Roche MagNA Pure 96 instrument (Roche Applied Science, Manheim, Germany), in accordance with the specific instrument's protocol and manufacturer's instructions. Immediately following the extraction, the samples were tested for SARS-CoV-2 by RT-qPCR and the remaining materials were aliquoted and stored at -80°C. One aliquot of each tested sample was delivered to Bar-Ilan University on dry ice and thawed once for the MMB-based testing. The MMB-based molecular assay of the positive samples was performed no later than three weeks after extraction.

To ensure unambiguous results, as our SARS-CoV-2-negative samples, including samples positive for other respiratory viruses, we used RNA extracts from late 2019 (i.e., before the coronavirus outbreak in Israel), stored at -80°C. One aliquot of each sample was delivered to Bar-Ilan University on dry ice and thawed once for the MMB-based testing. The samples were confirmed as negative for SARS-CoV-2 by RT-qPCR prior to testing them using the MMBbased molecular assay.

Synthetic oligonucleotides ( Table 1) 

The workflow for the MMB-based molecular assay is shown in Figure 2 . The RT-PCR reactions for the MMB-based detection were performed using a MasterCycler x50 PCR system (Eppendorf, Hamburg, Germany), which has a substantially faster temperature ramping rate than a standard RT-qPCR system 23 The cleaning procedure removes any residual fluorescent materials from previous tests, and allows reuse of the same cuvette without a measurable increase of background fluorescence.

The principles of the MMB system were described previously [16] [17] [18] 21 . Schematic representation of the MMB testing process and fully automated image analysis are depicted in Supplemental Figure S1 . Briefly, in the MMB system two electromagnets, one located on each side of the glass sample cell, aggregate the magnetic beads with their attached fluorescent molecules (Supplemental Figure S1A ). Alternating magnetic field gradients transport the compact aggregate mass in a periodic lateral motion in and out the orthogonal laser beam (Supplemental Figure S1C ). The peak-to-peak intensity of the modulated signal is proportional to the number of fluorescent molecules that are released to the solution following the PCR process.

To determine the number of PCR amplification cycles required by the MMB-based E-gene assay to reliably detect 10 copies per sample, we used in vitro transcribed RNA targets diluted in PCR-grade water. In the reaction mixture for the MMB-based E-gene assay, 5 µL of a clinical RNA sample were replaced with 5 µL of PCR-grade water, containing ~10 copies of the Egene synthetic target (i.e., ~2 copies/µL). As a negative control ("NTC" in 

To evaluate the analytical sensitivity of the MMB-based E-gene assay, we used in vitro transcribed RNA targets diluted in PCR-grade water to concentrations of 0.3, 0.6, 1.2, 2.4, 5, and 10 copies/µL. For a sample volume of 5 µL, these concentrations correspond to 1.5, 3, 6, 12, 25, and 50 copies/reaction. For each dilution, we tested a total of eight reactions ( = 8).

As a negative control, we used eight blank reactions ( = 8) containing 5 µL of PCR-grade water. The reaction mixtures were subjected to 5 min at 55°C, followed by 10 sec at 95°C, and then 40 amplification cycles of 5 sec at 95°C, 5 sec at 58°C, and 5 sec at 60°C. Following the amplification, the mixtures were incubated with magnetic beads for 3 minutes and tested using the MMB system.

Given a Gaussian distribution of blank values, the limit of blank (LoB) was calculated as 26

where and are the mean and standard deviation of the blank measurements, respectively.

The limit of detection (LoD) was calculated as 26

where is the standard deviation of the population of the low sample measurements (i.e., at a concentration of three target copies/reaction). The results were also analyzed using probit regression analysis (MedCalc v.19.6.1, MedCalc Software Ltd, Ostend, Belgium).

To The clinical sensitivity of the MMB-based assays was calculated as the percentage of SARS-CoV-2-positive patients that were identified as positive by each assay. Specificity was calculated as the percentage of SARS-CoV-2-negative patients that were identified as negative by the assay.

To determine the number of amplification cycles required by the MMB-based E-gene assay to reliably detect 10 copies of the in vitro transcribed RNA targets, we performed the calibration experiment depicted in Figure 3 . The signal to noise ratios (SNR) between the experimental samples and the negative controls ("NTC") after 30, 35, and 40 amplification cycles were 1.9, 5.7, and 7.4, respectively. Regardless of the number of amplification cycles, no significant difference in the normalized fluorescence signal was observed for the negative controls (four for each experiment, "NTC" in Figure 3 ). In all cases, the p-values, calculated using Student's t-test, were less than 0.0001.

To evaluate the analytical performance of the MMB-based E-gene assay, we tested samples containing increasing numbers of in vitro transcribed RNA targets, ranging from 0 to 50 copies/reaction ( Figure 4A ). Following 40 amplification cycles, the dynamic range of the assay, in which the signal is proportional to the number of copies, is narrow (~1-10 copies/reaction).

The calculated LoD of the MMB-based E-gene assay was 1.6 copies/reaction. Considering that each reaction contained 5 µL of the original sample, this is equivalent to 0.32 copies per one microliter of the original sample. Using the probit regression analysis of the dose response curve and the predetermined ROC cut-off value ( Figure 4B ), the calculated LoD was 3.3 copies/reaction, which is equivalent to 0.66 copies per one microliter of the original sample (CI95 2.7-5.7).

The clinical sensitivity and specificity of the MMB-based E-gene assay are presented in However, in case of the N1-gene MMB-based assay, the signal reduction tendency in samples with high values is much less pronounced than in the E-gene assay.

The current gold standard for COVID-19 diagnosis is based on direct detection of SARS-CoV-2 by RT-qPCR. This method is well established and highly sensitive, but it requires continuous monitoring of the fluorescence signal and maintaining optimal enzymatic conditions, and therefore the turnaround time is 90-120 minutes 22 , which limits its potential throughput. Here, we describe an alternative approach that significantly shortens the turnaround time while maintaining the same levels of sensitivity and specificity. The faster turnaround time of the MMB-based assay is achieved by detecting the fluorescence signal at the end of the amplification step (i.e., endpoint detection) rather than monitoring it in real time after each amplification cycle, and by using a much more sensitive optical detection system. The MMB detection system is ~150 times more sensitive than the direct optical detection system used in a standard RT-qPCR device 20 . Therefore, fewer and shorter amplification cycles are required to reach a detectable level of fluorescence. These changes, combined with the use of the Eppendorf X50 PCR MasterCycler, which has much higher temperature adjustment rates than a standard RT-qPCR 23, 24 , allow us to reduce the overall assay time to 30 minutes, which is 3-4 times faster than the current gold standard RT-qPCR. As a result, the ability to estimate the initial number of copies in the sample is limited to very low numbers of copies in the sample.

Institute (CLSI) guidelines 26 -is 1.6 copies/reaction (0.32 copies/µL of the sample), which is on par with the reported LoD of commercially available RT-qPCR-based SARS-CoV-2 detection kits 27, 28 . Using probit regression analysis, the LoD is 3.3 copies/reaction (CI95 2.7-5.67). The discrepancy between the LoD values can be explained by the inherent differences in the two calculation methods and by the limited number of tested samples.

Overall, as shown in Figure 5 , the MMB-based E-gene assay has 100% specificity and 97.8% The costs associated with the MMB-based molecular assay are different than a standard RT-qPCR assay in two aspects: equipment and reagents. The equipment used for the MMB-based molecular assays comprises a dedicated optical detection system (referred to as the MMB system) 30 and a rapid PCR cycler, whose combined cost is expected to be cheaper than the cost of a standard RT-qPCR system, which ranges between $30,000 and $50,000. The reagents used in the MMB-based molecular assay are similar to the ones used in a standard RT-qPCR assay, excluding the magnetic beads and the modified double-quenched hydrolysis probe, whose combined cost (~$0.2/reaction) is negligible compared to the overall cost of the other RT-qPCR reagents.

Finally, a limiting factor of the current single-channel MMB system is its relatively low throughput (~30 samples/hour). Ongoing modification to the MMB system will enable detection of 96 samples in a 96-well plate (rather than a single cuvette at a time). Combining pre-and post-processing robots with a 96-well plate MMB system will eliminate the need for manual manipulation of the samples and enable high throughput sample testing.

Here, based on our established MMB technology, we presented a rapid molecular assay to detect SARS-CoV-2-specific RNA sequences. The MMB-based E-gene molecular assay has J o u r n a l P r e -p r o o f demonstrated an LoD of 1.6 copies/reaction. In tests using 309 clinical samples from SARS-CoV-2-positive and negative patients with a wide range of initial viral loads ( ≤ ), the clinical sensitivity and specificity were 97.8 and 100%, respectively. In addition, the signal of the MMB-based molecular assays was correlated to the initial viral load, and the total turnaround time (30 minutes) was much shorter than the average RT-qPCR test (90-120 minutes).

The proposed SARS-CoV-2 MMB-based assay can be adjusted to detect a wide variety of pathogens, viral or other. Implementation of the presented assay with a high throughput detection device will enable rapid screening of large groups of people in the community and improve the management of current SARS-CoV-2 pandemic. A standard double-quenched hydrolysis probe has a second quencher ("Q2") between the fluorescent reporter dye ("R"), which is located at the 5', and the first quencher ("Q1"), which is located at the 3'. B) A modified doublequenched hydrolysis probe has two quenchers ("Q1" and "Q2") and a biotin molecule ("B") on the same 5' nucleotide as the fluorescent reporter dye ("R"). For samples with

Estimating the reproductive number and the outbreak size of COVID-19 in Korea

Rapid antigen-based testing for respiratory syncytial virus: moving diagnostics from bench to bedside?

Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis

The real-time polymerase chain reaction

Real-time quantitative PCR, pathogen detection and MIQE

Loop-mediated isothermal amplification of DNA

Loop-mediated isothermal amplification (LAMP): a rapid, accurate, and cost-effective diagnostic method for infectious diseases

Evaluation of Alere i Influenza A&B for Rapid Detection of Influenza Viruses A and B

Aguero-Rosenfeld ME: Performance of Abbott ID Now COVID-19 Rapid Nucleic Acid Amplification Test Using Nasopharyngeal Swabs Transported in Viral Transport Media and Dry Nasal Swabs in a New York City Academic Institution

Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2

Rapid Detection of COVID-19 Coronavirus Using a Reverse Transcriptional Loop-Mediated Isothermal Amplification (RT-LAMP) Diagnostic Platform

A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples

A novel fluorescence-based assay for the rapid detection and quantification of cellular deoxyribonucleoside triphosphates

Improved PCR-Based Detection of Soil Transmitted Helminth Infections Using a Next-Generation Sequencing Approach to Assay Design

Detection of fluorescent-labeled probes at subpicomolar concentrations by magnetic modulation

Magnetic modulation biosensing for rapid and homogeneous detection of biological targets at low concentrations

Highly sensitive and specific Zika virus serological assays using a magnetic modulation biosensing system

Rapid and Sensitive Detection of Repetitive Nucleic Acid Sequences Using Magnetically Modulated Biosensors

Detecting nucleic acid fragments in serum using a magnetically modulated sandwich assay

Rapid homogenous detection of the Ibaraki virus NS3 cDNA at picomolar concentrations by magnetic modulation

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

CFX96 Touch™ Real-Time PCR Detection System Specifications. 2020. 24. Eppendorf: Eppendorf Mastercycler x50 specifications

Improving the Sensitivity of Fluorescence-Based Immunoassays by Photobleaching the Autofluorescence of Magnetic Beads

Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guidelines

SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity

Identification of protein-protein interactions using a magnetic modulation biosensing system

The authors would like to thank Dr. Meir Cohen for technical assistance and Dr. Paul Olivo for critical review of the manuscript. James Ballard provided an editorial review of the manuscript.J o u r n a l P r e -p r o o f